NF1 is a nervous system disorder that affects ... The drugmaker also warned that Gomekli may harm an unborn baby. Women should take a pregnancy test before starting treatment and use birth control ...

According to a memo from the Department of the Navy obtained by ABC 10News, a stop-work order was issued last week to Marine ...

Women with an unplanned cesarean delivery had increased odds of developing postpartum depression and attending postpartum ...

Newly leaked National Security Council (NSC) documents have exposed secret U.S. strategies aimed at prolonging the Ukraine war and targeting Russia’s infrastructure and civilians. The documents reveal ...

Cardi B and Stefon Diggs were photographed out together on Valentine's Day, six months after the rapper filed for divorce ...

A baby's eye color is controlled by the amount and type of pigment ... albinism and diabetics retinopathy. Ludwig CA, Callaway NF, Fredrick DR, Blumenkranz MS, Moshfeghi DM. What colour are newborns’ ...

Demand for plant-based baby and infant foods is rising significantly — a report ... “The Panel considers that there are no concerns with regard to the toxicity of the NF [novel food],” says the EFSA. ...

Gomekli is the first medication approved for both adult and pediatric patients with NF1-PN. The Food and Drug Administration (FDA) has approved Gomekli ™ (mirdametinib) for the treatment of ...

Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable to complete surgical resection are indicated in the approval.

Opens in a new tab or window The FDA on Tuesday approved mirdametinib (Gomekli) for adults and kids ages 2 and up with neurofibromatosis type 1 (NF1). Approval of the MEK inhibitor is specifically ...

The disease, neurofibromatosis type 1 (NF1), is technically not cancer as the tumors that form are benign. But NF1 can lead to cancers. Even if a patient’s tumors aren’t cancerous, they are ...

(RTTNews) - SpringWorks Therapeutics Inc. (SWTX) announced that the U.S. Food and Drug Administration has approved GOMEKLI (mirdametinib), SpringWorks MEK inhibitor, for the treatment of adult and ...